1 / 23

Alison Drake International AIDS Society Conference July 18, 2011

Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum: results of a randomized clinical trial. Alison Drake International AIDS Society Conference July 18, 2011. Abstracts at IAS 2011. Oral Abstract Session Maternal Health and Paediatric Outcomes

mason
Télécharger la présentation

Alison Drake International AIDS Society Conference July 18, 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum: results of a randomized clinical trial Alison Drake International AIDS Society Conference July 18, 2011

  2. Abstracts at IAS 2011 • Oral Abstract Session Maternal Health and Paediatric Outcomes • TUAB0202: Tuesday 2:30 – 4:00, MR 4 • Poster Exhibitions • MOPE174: Monday 12:30 – 2:30 • TUPE268: Tuesday 12:30 – 2:30

  3. MTCT in non-breastfeeding populations Postnatal Tx rate (6 mo) Maternal HAART Maternal HAART 1 - 2% sdNVP Maternal ZDV + 3TC (1 wk) ZDV 1 - 2% Pregnancy Delivery Postpartum

  4. MTCT in breastfeeding populations Cessation of BF Postnatal Tx rate (6 mo) Maternal HAART Maternal HAART or Infant NVP 3 - 5% sdNVP Maternal ZDV + 3TC (1 wk) ZDV 8 - 10% Pregnancy Delivery Postpartum

  5. MTCT in breastfeeding populations • Access to ARVs for PMTCT not universal • 53% coverage in low- and middle- income countries (WHO 2010) • Alternative strategies needed to reduce postnatal transmission Cessation of BF Postnatal Tx rate (6 mo) Maternal HAART Maternal HAART or Infant NVP 3 - 5% sdNVP Maternal ZDV + 3TC (1 wk) ZDV 8 - 10% Pregnancy Delivery Postpartum

  6. HSV-2 infection in HIV-1 infected women • Prevalence 75% to > 95% • Suppressive therapy • Reduces plasma HIV-1 RNA 0.25 - 0.5 log • 0.18 log greater reduction with valacyclovir (Ludema 2011) • Effect on breast milk HIV-1 RNA or MTCT unknown

  7. Aims • To evaluate the effect of valacyclovir suppressive therapy administered during late pregnancy and for 12 months postpartum on: • Plasma HIV-1 RNA levels • Breast milk HIV-1 RNA detection and levels

  8. Study design • Inclusion criteria • Procedures • Double blind RCT • 500 mg valacyclovir • or placebo bid • PMTCT ARVs • ZDV + sdNVP • HIV-1/HSV-2 seropositive • ≥ 18 years of age • HAART ineligible • CD4 > 250 cells/mm3 • Seeking ANC in Nairobi, Kenya • Deliver and remain in Nairobi 12 months postpartum

  9. Study design • Inclusion criteria • Procedures • Double blind RCT • 500 mg valacyclovir • or placebo bid • PMTCT ARVs • ZDV + sdNVP • HIV-1/HSV-2 seropositive • ≥ 18 years of age • HAART ineligible • CD4 > 250 cells/mm3 • Seeking ANC in Nairobi, Kenya • Deliver and remain in Nairobi 12 months postpartum Screen Enroll & Randomize Blood & breast milk Delivery Pregnancy Postpartum 28-32wk 38wk 34wk 6wk 2wk 14wk 6mo 12mo

  10. Screening, enrollment, and follow-up April 2008 – June 2009 359 screened Ineligible * 85 HSV-2 67 CD4 70 HAART 24 Residence 211 eligible 148 enrolled 74 placebo 74 valacyclovir 1 LTFU 73 included in analysis 1 LTFU 73 included in analysis * not mutually exclusive

  11. Baseline and infant characteristics

  12. Postpartum plasma HIV-1 RNA levels Placebo Valacyclovir

  13. Postpartum plasma HIV-1 RNA levels Placebo Valacyclovir

  14. Postpartum plasma HIV-1 RNA levels Placebo Valacyclovir

  15. Postpartum plasma HIV-1 RNA levels Placebo Valacyclovir p 2wk PVL 2- 6 wk rate of ∆ 3.102.08 2.83 1.48 0.11 <0.001 0.60 lower (95% CI 0.92 – 0.28)

  16. Postpartum plasma HIV-1 RNA levels Placebo Valacyclovir p 6 wk – 12 mo rate of ∆ Mean (95% CI) difference 0.03 0.02 0.51 lower (0.73 – 0.30) 0.3 <0.001

  17. HIV-1 RNA detection in breast milk

  18. Breast milk HIV-1 RNA levels Placebo Valacyclovir Breast milk Plasma Median (IQR) 6 wk 14 wk 2.42 (1.70 – 3.35)1.70 (1.70 – 2.96) 1.70 (1.70 – 2.57) 1.70 (1.70 – 1.70)

  19. Breast milk and plasma HIV-1 RNA levels Placebo Valacyclovir Breast milk Plasma Median (IQR) 6 wk 14 wk 2.42 (1.70 – 3.35)1.70 (1.70 – 2.96) 1.70 (1.70 – 2.57) 1.70 (1.70 – 1.70)

  20. Risk of infant HIV-1 transmission n = 6 n = 4

  21. Conclusions • Valacyclovir reduced • Early breast milk HIV-1 RNA detection • Plasma HIV-1 RNA 0.51 log • Plasma results consistent with other trials • Impact of valacyclovir on MTCT may differ from heterosexual transmission • Prolonged exposure to bodily fluids • 0.4 log lower viral load associated with reduced risk of postnatal MTCT (Neveu 2011)

  22. Implications • Valacyclovir is an appealing intervention • Valacyclovir suppressive therapy, in conjunction with PMTCT ARVs, should be evaluated as an intervention to reduce postnatal MTCT and improve maternal health

  23. Acknowledgments • Funding • NIH R03 5R03HD057773-02 • NIH ARRA 5R03HD057773-02S1 • University of Washington CFAR • P30 AI027757 • CFAR STD Pre-doctoral Training Grant 5T32AI007140-33 • Puget Sound Partners for Global Health • UW Royalty Research Fund Study participants Mathare staff DSMB GlaxoSmithKline • University of Washington • Carey Farquhar • Alison Roxby • Anna Wald • Grace John-Stewart • Barbra Richardson • Julie Overbaugh • Jane Hitti • Sandy Emery University of Nairobi • James Kiarie • Francisca Ongecha-Owuor

More Related